BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Crohn's Disease readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Crohn's Disease\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07683325-9627@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:ontunisertib: Phase 2 readout est. (NCT07683325)
DESCRIPTION:ontunisertib\, phase 2\, Fibrostenosing Crohn's Disease.\nStudy
 : NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunise
 rtib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease\n
 Estimated primary completion: 31 December 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/ontunisertib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07683325
URL:https://assetmemo.bio/drug/ontunisertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
